OpGen Raises $1.1M to Commercialize Antibiotic-resistant Microbe Detection Test | GenomeWeb

NEW YORK (GenomeWeb) – OpGen has raised about $1.1 million toward a targeted $1.5 million financing round, the firm disclosed in a regulatory document recently.

A spokesperson for the Gaithersburg, Md.-based microbial genetics analysis firm said that the initial funds are part of a Series B financing round that OpGen expects to close in the fall. It will use the money to commercialize the Acuitas MDRO Gene Test, a molecular test for identifying patients at risk of harboring antibiotic-resistant disease-causing microbes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.